A new serum biomarker emerges for the prodromal phase of Alzheimer’s disease
Recent research published in the Journal of Neurochemistry reveals a significant decline in metabotropic glutamate receptor 3 (mGlu3R) protein levels in the serum of individuals with mild cognitive impairment (MCI), a condition often preceding Alzheimer’s disease (AD). The study demonstrates that mGlu3R expression is reduced within the amyloid plaque niche in both human and mouse AD brains, with protein levels inversely correlating with amyloid burden. This work builds on prior findings that astroglial mGlu3R promotes non-amyloidogenic APP processing and amyloid-β clearance, suggesting its downregulation represents an early glial dysfunction in AD pathogenesis.
Study Significance: The identification of mGlu3R as a detectable serum biomarker during the mild cognitive impairment stage offers a potential tool for earlier, less invasive diagnosis of prodromal Alzheimer’s disease. For hepatology professionals, this research underscores the critical importance of biomarker discovery in chronic, progressive diseases, mirroring the ongoing search for reliable non-invasive markers for liver fibrosis, non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma. The methodological approach—linking serum analyte levels to specific pathological processes in the target organ—provides a translational framework applicable to liver disease research, where connecting circulating biomarkers to hepatic histopathology remains a central challenge.
Source →Stay curious. Stay informed — with Science Briefing.
This is a one time Briefing, Upgrade to continue.
Upgrade and get 50% Off — Coupon: ERWMCWYU
